Status of atmospheric neutrino(mu)<-->neutrino(tau) oscillations and decoherence after the first K2K spectral data

We review the status of nu_mu-->nu_tau flavor transitions of atmospheric neutrinos in the 92 kton-year data sample collected in the first phase of the Super-Kamiokande (SK) experiment, in combination with the recent spectral data from the KEK-to-Kamioka (K2K) accelerator experiment (including 29 single-ring muon events). We consider a theoretical framework which embeds flavor oscillations plus hypothetical decoherence effects, and where both standard oscillations and pure decoherence represent limiting cases. It is found that standard oscillations provide the best description of the SK+K2K data, and that the associated mass-mixing parameters are determined at 1 sigma (and d.o.f.=1) as: Delta m^2=(2.6 +- 0.4)x10^{-3} eV^2 and sin^2(2theta)=1.00+0.00-0.05. As compared with standard oscillations, the case of pure decoherence is disfavored, although it cannot be ruled out yet. In the general case, additional decoherence effects in the nu_mu-->nu_tau channel do not improve the fit to the SK and K2K data, and upper bounds can be placed on the associated decoherence parameter. Such indications, presently dominated by SK, could be strengthened by further K2K data, provided that the current spectral features are confirmed with higher statistics. A detailed description of the statistical analysis of SK and K2K data is also given, using the so-called ``pull'' approach to systematic uncertainties.Comment: 18 pages (RevTeX) + 12 figures (PostScript

An Anglo-Saxon execution cemetery at Walkington Wold, Yorkshire

This paper presents a re-evaluation of a cemetery excavated over 30 years ago at Walkington Wold in east Yorkshire. The cemetery is characterized by careless burial on diverse alignments, and by the fact that most of the skeletons did not have associated crania. The cemetery has been variously described as being the result of an early post-Roman massacre, as providing evidence for a ‘Celtic’ head cult or as an Anglo-Saxon execution cemetery. In order to resolve the matter, radiocarbon dates were acquired and a re-examination of the skeletal remains was undertaken. It was confirmed that the cemetery was an Anglo-Saxon execution cemetery, the only known example from northern England, and the site is set into its wider context in the paper

Deviation of Neutrino Mixing from Bi-maximal

We have studied how observables of the neutrino mixing matrix can link up with the ones in the quark sector. The deviation from the bi-maximal flavor mixing is parameterized using a 3 x 3 unitary matrix. The neutrino mixings are investigated supposing this unitary matrix to be hierarchical like the quark mixing matrix. We obtain the remarkable prediction |U_{e3}| >= 0.03 from the experimentally allowed range tan^2 theta_{sol} = 0.24 ~ 0.89. The CP violation in neutrino oscillations is expected to be very small.Comment: Some references are adde

Neutral-Current Atmospheric Neutrino Flux Measurement Using Neutrino-Proton Elastic Scattering in Super-Kamiokande

Recent results show that atmospheric $\nu_\mu$ oscillate with $\delta m^2 \simeq 3 \times 10^{-3}$ eV$^2$ and $\sin^2{2\theta_{atm}} \simeq 1$, and that conversion into $\nu_e$ is strongly disfavored. The Super-Kamiokande (SK) collaboration, using a combination of three techniques, reports that their data favor $\nu_\mu \to \nu_\tau$ over $\nu_\mu \to \nu_{sterile}$. This distinction is extremely important for both four-neutrino models and cosmology. We propose that neutrino-proton elastic scattering ($\nu + p \to \nu + p$) in water \v{C}erenkov detectors can also distinguish between active and sterile oscillations. This was not previously recognized as a useful channel since only about 2% of struck protons are above the \v{C}erenkov threshold. Nevertheless, in the present SK data there should be about 40 identifiable events. We show that these events have unique particle identification characteristics, point in the direction of the incoming neutrinos, and correspond to a narrow range of neutrino energies (1-3 GeV, oscillating near the horizon). This channel will be particularly important in Hyper-Kamiokande, with $\sim 40$ times higher rate. Our results have other important applications. First, for a similarly small fraction of atmospheric neutrino quasielastic events, the proton is relativistic. This uniquely selects $\nu_\mu$ (not $\bar{\nu}_\mu$) events, useful for understanding matter effects, and allows determination of the neutrino energy and direction, useful for the $L/E$ dependence of oscillations. Second, using accelerator neutrinos, both elastic and quasielastic events with relativistic protons can be seen in the K2K 1-kton near detector and MiniBooNE.Comment: 10 pages RevTeX, 8 figure

Leptogenesis and rescattering in supersymmetric models

The observed baryon asymmetry of the Universe can be due to the $B-L$ violating decay of heavy right handed (s)neutrinos. The amount of the asymmetry depends crucially on their number density. If the (s)neutrinos are generated thermally, in supersymmetric models there is limited parameter space leading to enough baryons. For this reason, several alternative mechanisms have been proposed. We discuss the nonperturbative production of sneutrino quanta by a direct coupling to the inflaton. This production dominates over the corresponding creation of neutrinos, and it can easily (i.e. even for a rather small inflaton-sneutrino coupling) lead to a sufficient baryon asymmetry. We then study the amplification of MSSM degrees of freedom, via their coupling to the sneutrinos, during the rescattering phase which follows the nonperturbative production. This process, which mainly influences the (MSSM) $D-$flat directions, is very efficient as long as the sneutrinos quanta are in the relativistic regime. The rapid amplification of the light degrees of freedom may potentially lead to a gravitino problem. We estimate the gravitino production by means of a perturbative calculation, discussing the regime in which we expect it to be reliable.Comment: (20 pages, 6 figures), references added, typos corrected. Final version in revte

Factors Associated with Revision Surgery after Internal Fixation of Hip Fractures

Background: Femoral neck fractures are associated with high rates of revision surgery after management with internal fixation. Using data from the Fixation using Alternative Implants for the Treatment of Hip fractures (FAITH) trial evaluating methods of internal fixation in patients with femoral neck fractures, we investigated associations between baseline and surgical factors and the need for revision surgery to promote healing, relieve pain, treat infection or improve function over 24 months postsurgery. Additionally, we investigated factors associated with (1) hardware removal and (2) implant exchange from cancellous screws (CS) or sliding hip screw (SHS) to total hip arthroplasty, hemiarthroplasty, or another internal fixation device. Methods: We identified 15 potential factors a priori that may be associated with revision surgery, 7 with hardware removal, and 14 with implant exchange. We used multivariable Cox proportional hazards analyses in our investigation. Results: Factors associated with increased risk of revision surgery included: female sex, [hazard ratio (HR) 1.79, 95% confidence interval (CI) 1.25-2.50; P = 0.001], higher body mass index (fo

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation &lt;92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg–800 mg (depending on weight) given intravenously. A second dose could be given 12–24 h later if the patient's condition had not improved. The primary outcome was 28-day mortality, assessed in the intention-to-treat population. The trial is registered with ISRCTN (50189673) and ClinicalTrials.gov (NCT04381936). Findings: Between April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0·85; 95% CI 0·76–0·94; p=0·0028). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50%; rate ratio 1·22; 1·12–1·33; p&lt;0·0001). Among those not receiving invasive mechanical ventilation at baseline, patients allocated tocilizumab were less likely to reach the composite endpoint of invasive mechanical ventilation or death (35% vs 42%; risk ratio 0·84; 95% CI 0·77–0·92; p&lt;0·0001). Interpretation: In hospitalised COVID-19 patients with hypoxia and systemic inflammation, tocilizumab improved survival and other clinical outcomes. These benefits were seen regardless of the amount of respiratory support and were additional to the benefits of systemic corticosteroids. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

Background: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. Methods: This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy [RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and consenting patients were randomly assigned (1:1) to receive either usual care alone (usual care group) or usual care plus high-titre convalescent plasma (convalescent plasma group). The primary outcome was 28-day mortality, analysed on an intention-to-treat basis. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936. Findings: Between May 28, 2020, and Jan 15, 2021, 11558 (71%) of 16287 patients enrolled in RECOVERY were eligible to receive convalescent plasma and were assigned to either the convalescent plasma group or the usual care group. There was no significant difference in 28-day mortality between the two groups: 1399 (24%) of 5795 patients in the convalescent plasma group and 1408 (24%) of 5763 patients in the usual care group died within 28 days (rate ratio 1·00, 95% CI 0·93–1·07; p=0·95). The 28-day mortality rate ratio was similar in all prespecified subgroups of patients, including in those patients without detectable SARS-CoV-2 antibodies at randomisation. Allocation to convalescent plasma had no significant effect on the proportion of patients discharged from hospital within 28 days (3832 [66%] patients in the convalescent plasma group vs 3822 [66%] patients in the usual care group; rate ratio 0·99, 95% CI 0·94–1·03; p=0·57). Among those not on invasive mechanical ventilation at randomisation, there was no significant difference in the proportion of patients meeting the composite endpoint of progression to invasive mechanical ventilation or death (1568 [29%] of 5493 patients in the convalescent plasma group vs 1568 [29%] of 5448 patients in the usual care group; rate ratio 0·99, 95% CI 0·93–1·05; p=0·79). Interpretation: In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Funding: UK Research and Innovation (Medical Research Council) and National Institute of Health Research